Drug
Abciximab clinical trials
Also written ReoPro.
- studies test it
- 34
- open now
- 0
- in phase 3
- 10
- first study started
- 1991
How studies write it
Studies that test it under each name
Brand
- ReoPro
- 10
Combined with it in one product
Studies by the year they started
33 studies that test it; most in 2006 (6)
| Year | Studies |
|---|---|
| 1991 | 1 |
| 1993 | 1 |
| 1995 | 1 |
| 2000 | 1 |
| 2002 | 3 |
| 2003 | 5 |
| 2004 | 2 |
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2012 | 1 |
| 2013 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 1
- Phase 2
- 8
- Phase 3
- 10
- Phase 4
- 15
- No phase
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 28
Centocor, Inc. (4) · Deutsches Herzzentrum Muenchen (3) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · Yonsei University (2) · Laval University (2) · University of Zurich (2) · University Hospital Tuebingen (2) · Boehringer Ingelheim (1)
Often tested with
Tested in the same studies.
Heparin (2) · Enoxaparin (1) · Prasugrel (1) · Bivalirudin (1) · Clopidogrel (1)
Studies
Open first, then newest update. How each study uses Abciximab is read from its arms, and is right about nine times in ten.
Testing it · 34
- Intracoronary Bolus Only Compared With Intravenous Bolus and 12-hours Infusion of Abciximab in Non-ST Elevation Myocardial Infarction.TerminatedPhase 4Seoul National University HospitalNCT01080638Written as glycoprotein IIb/IIIa inhibitor (abciximab)
- ReoPro and Retavase to Treat Acute StrokeCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00046293Written as Reopro
- Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI PatientsStatus unknownPhase 2ISU Abxis Co., Ltd.NCT03087539Written as Abciximab
- Stroke Prevention With Abciximab in Carotid EndarterectomyWithdrawnPhase 1/2University of RochesterNCT00178451Written as Abciximab
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-platelet Therapy, in Patients Undergoing High-risk Coronary AngioplastyCompletedPhase 3Centocor, Inc.NCT00269893Written as Abciximab
- A Study Comparing the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Combination With Two Different Heparin Regimens in Patients Undergoing Percutaneous Coronary Intervention.CompletedPhase 3Centocor, Inc.NCT00269880Written as Abciximab
- A Study Evaluating the Efficacy and Safety of Abciximab, an Anti-Platelet Therapy, in Patients With Unstable Angina Not Responding to Standard Medical Therapy Who Are Eligible for Coronary AngioplastyCompletedPhase 3Centocor, Inc.NCT00269906Written as Abciximab
- Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain CrisisWithdrawnPhase 2St. Louis UniversityNCT01932554Written as Abciximab
- Full Dose Tenecteplase (TNK-tPA) Together With Heparin Sodium, Full Dose Tenecteplase With Enoxaparin, Half Dose Tenecteplase Together With Abciximab and Heparin Sodium in Patients With Acute Myocardial Infarction (AMI)CompletedPhase 3Boehringer IngelheimNCT02181985Written as Abciximab
- A Randomized Trial of Intracoronary Reopro to Improve Coronary Microvascular FunctionStatus unknownNot applicableUniversity of MelbourneNCT02105870Written as Abciximab
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MI and Rescue-PCICompletedPhase 4Olivier F. BertrandNCT00440895Written as Abciximab
- Efficacy of Combination of IntraCoronary Bolus Abciximab and Aspiration Thrombectomy in STEMICompletedPhase 4Yonsei UniversityNCT01404507Written as Gp 2b 3a inhibitor
- Tailored Antiplatelet Therapy During Percutaneous Coronary Intervention in Patients With Diabetes MellitusCompletedPhase 4Seoul National University Bundang HospitalNCT01475552Written as Abciximab
- Randomized Comparison of Abciximab Plus Heparin With Bivalirudin in Acute Coronary SyndromeCompletedPhase 4Deutsches Herzzentrum MuenchenNCT00373451Written as Abciximab + UFH
- A Randomized Trial of Early Discharge After Trans-radial Stenting of Coronary Arteries in Acute MICompletedPhase 4Laval UniversityNCT00440778Written as Abciximab
- Efficacy Study on Early Versus Late Abciximab Administration During Primary Coronary AngioplastyCompletedPhase 4University of PisaNCT00354406Written as abciximab
- ReoPro and Retavase to Restore Brain Blood Flow After StrokeCompletedPhase 2National Institute of Neurological Disorders and Stroke (NINDS)NCT00039832Written as Abciximab (ReoPro) and Reteplase (Retavase)
- Intravenous Versus Intracoronary Use of AbciximabCompletedNot applicableUniversity Hospital, Gentofte, CopenhagenNCT00685464Written as Abciximab
- Comparison of Drug Eluting and Bare Metal Stents With or Without Abciximab in ST Elevation Myocardial InfarctionCompletedPhase 4Catharina Ziekenhuis EindhovenNCT00986050Written as Abciximab
- A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II)TerminatedPhase 3Centocor, Inc.NCT00073372Written as Abciximab
See all 34 studies that test Abciximab →
As the comparator · 5 — what is tested is compared with Abciximab
- Comparative Study of ALX-0081 Versus GPIIb/IIIa Inhibitor in High Risk Percutaneous Coronary Intervention (PCI) PatientsCompletedPhase 2Ablynx, a Sanofi companyNCT01020383Written as ReoPro®
- Intracoronary Abciximab With Clearway CatheterTerminatedPhase 3Gennaro SardellaNCT00894023Written as IV abciximab
- Efficacy Of Eptifibatide Compared To Abciximab In Primary Percutaneous Coronary Intervention (PCI) For Acute ST Elevation Myocardial Infarction (STEMI)CompletedPhase 3GlaxoSmithKlineNCT00426751Written as Abciximab
- Randomized Trial of Standard vs ClearWay-infused Abciximab and Thrombectomy for Myocardial InfarctionStatus unknownPhase 4CLI FoundationNCT01499407Written as Abciximab
- FATA: Randomized Study on Facilitated Angioplasty With Tirofiban or AbciximabCompletedPhase 4University of BolognaNCT00383136Written as Abciximab
Codes
What other systems call Abciximab · ClinicalTrials.gg INT006686
- MeSH (NLM) D000077284AbciximabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) X85G7936GVABCIXIMABConfirmed FDA, NLM
- RxNorm 83929One source FDA
- NCI Thesaurus C76128AbciximabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000077284 | Abciximab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | X85G7936GV | ABCIXIMAB | Confirmed FDA, NLM |
| RxNorm | 83929 | — | One source FDA |
| NCI Thesaurus | C76128 | Abciximab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.